Programmed death-ligand 1 (PD-L1) by Immunohistochemistry (IHC)
The PD-L1 IHC 28-8 pharmDx assay is a qualitative immunohistochemical test using Monoclonal Rabbit Anti-PD-L1, Clone 28-8, designed for use on formalin-fixed, paraffin-embedded (FFPE) tumor tissues. It is FDA-approved as a companion diagnostic for multiple tumor types, including Non-small cell lung cancer (NSCLC), Squamous cell carcinoma of the head and neck (SCCHN) and Urothelial carcinoma (UC) and provides essential information for patient selection in immunotherapy.
PD-L1 protein expression is assessed by determining the percentage of evaluable tumor cells showing partial or complete membrane staining at any intensity. Expression levels guide therapeutic decisions regarding the use of immune checkpoint inhibitors such as nivolumab (Opdivo®) and pembrolizumab (Keytruda®). Other FDA-approved PD-L1 IHC assays (22C3, SP142, SP263) may use different scoring systems, such as tumor proportion score (TPS) or combined positive score (CPS), incorporating tumor cells and tumor-associated immune cells.
PD-L1 is a key immune checkpoint biomarker. Its expression on tumor cells allows evasion of T-cell–mediated immunity, while blockade with PD-1/PD-L1 inhibitors enhances antitumor immune activity. Several PD-L1 inhibitors, including atezolizumab, durvalumab, nivolumab, and pembrolizumab, are approved for clinical use across multiple cancer types.
- Identifies patients with PD-L1–positive tumors who may benefit from checkpoint inhibitor therapy
- Helps predict response to PD-1/PD-L1 inhibitors across several malignancies.
- Serves as a companion diagnostic for FDA-approved immunotherapies in NSCLC, SCCHN, UC, cervical carcinoma, gastric/GEJ adenocarcinoma, HCC, and melanoma
NSCLC: PD-L1 positivity defined by TPS ≥1%, ≥5%, or ≥10%, depending on indication.
SCCHN: PD-L1 positivity defined by ≥1% expression.
UC: PD-L1 positivity defined by ≥1% expression.
Other tumors: Cutoffs vary by assay and indication (TPS vs. CPS vs. IC scoring).
Several scoring systems are in use:
- TPS (Tumor Proportion Score): % of tumor cells with PD-L1 expression.
- CPS (Combined Positive Score): includes tumor and immune cells divided by total tumor cells.
- IC Scoring (Immune Cells): % of tumor area occupied by PD-L1–positive immune cells (SP142 assay).
Interpretation must follow assay-specific guidelines and clinical indication.
Negative (<1%) – No significant PD-L1 expression detected
Formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
Fixed tissues are stable at room temperature for longer.
3 - 5 days.
- Diagn Pathol. 2018 Feb 9;13(1):12. [PMID: 29426340]
- J Clin Oncol. 2017 Dec 1;35(34):3867-3876. [PMID: 29053400]
- Ther Drug Monit. 2018 Feb;40(1):9-16. [PMID: 29084031]
- J Thorac Dis. 2019 Jan;11(Suppl 1):S89-S101. [PMID: 30775032]
- Bladder Cancer. J Clin Oncol. 2016; 34(26): 3119-25. [PMID: 27269937]